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A B S T R A C T
A newly licensed biosimilar product containing inﬂiximab as the active pharmaceutical ingredient has
recently been marketed under the brand name Remsima1. We have evaluated the stability of Remsima1
diluted in sodium chloride solution and stored in polyoleﬁn bags at 2–8 C using a range of techniques to
assess the physico-chemical and functional integrity of the drug over time. The methods and techniques
employed are fully compliant with NHS (UK) guidance for evaluating the stability of biologicals, enabling
the data to be used for the application of an extended shelf-life to Remsima products in the UK, when
prepared under a Section 10 exemption or a Specials Licence. The results clearly demonstrate physico-
chemical and functional stability of the drug over the 7 day period of the study, when prepared as
described here under aseptic conditions in accordance with the Summary of manufacturers Product
Characteristics.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Inﬂiximab (originally marketed as Remicade1 by Merck, Sharp
and Dohme) is a chimeric human-murine IgG1 monoclonal
antibody (mAb) which acts as a cytokine modulator (Knight
et al., 1993). It works by selectively binding to soluble and
transmembrane forms of TNF-a, thereby reducing the pro-
inﬂammatory signalling of this cytokine (Wong et al., 2008;
Couriel et al., 2000). Inﬂiximab is indicated for the treatment of
rheumatoid arthritis (in combination with methotrexate) when
treatment with other anti-rheumatic drugs have failed, and for
ankylosing spondylitis. Dosing for all indications is according to
body mass and ranges from 3 to 7.5 mg/kg (Electronic Medicines
Compendium, 2015a). The recent patent expiry of Remicade1 has
resulted in the emergence of biosimilar versions of inﬂiximab, one
of which is Remsima1, marketed in the United Kingdom by NAPP
Pharmaceuticals. The pharmaceutical form, strength, size and
composition of this medicinal product is reported to be the same as* Corresponding author.
E-mail address: a.watts@bath.ac.uk (A.G. Watts).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijpharm.2015.10.016
0378-5173/ã 2015 The Authors. Published by Elsevier B.V. This is an open access articthat of the Remicade1 brand, according to the relevant Summary of
manufacturers Product Characteristics (SmPC) (Electronic Medi-
cines Compendium, 2015a,b).
The manufacturers of both Remicade1 and Remsima1 have
stated that the medicinal product is physico-chemically stable for
up to 24 h when stored at 25 C and once prepared, storage should
not exceed 24 h at 2–8 C. Such short shelf-lives are not uncommon
for this class of product, with the vast majority of antibody
therapeutics being assigned storage limits of either 24 or 48 h, once
prepared in ready to use form. However, it is commonly considered
that these short shelf-lives are applied to limit any potential risk
from microbiological contamination introduced during prepara-
tion, as opposed to them reﬂecting an inherent lack of physico-
chemical stability of the drug.
In the United Kingdom, extended shelf-lives can be applied to
antibody therapeutics prepared under a Section 10 exemption or a
Specials Licence, where robust data exists to support them. Here,
the National Health Service (NHS) Guidance document ‘A Standard
Protocol for Deriving and Assessment of Stability; Part 2: Aseptic
Preparations (Biopharmaceuticals). Edition 1, October 2012’, serves to
deﬁne the criteria necessary for a robust study of stability, towards
the application of an extended shelf-life to the clinical product
(Santillo, 2012).le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Guidance requirements for design of a robust stability study, with the elements employed in this study listed alongside to demonstrate compliance (Santillo, 2012).
Study element Guidance requirement Element employed in this study
Diluent As speciﬁed in SmPC 0.9% sodium chloride solution
Containers Non-PVC Polyoleﬁn (Freeﬂex1)
Storage Refrigerated in absence of light Refrigerated in absence of light
Room temperature (25  2 C) Room temperature (24 h) for clinically common (0.84 mg/mL)
Concentrations Low & high clinically signiﬁcant Three concentrations tested. Clinically low (0.60 mg/mL), clinically common (0.84 mg/
mL) and clinically high (1.88 mg/mL)
Storage period Normally 48 h–3 months Seven day storage
Sampling
strategy
For studies <6 months, at least 4 sampling points in addition to
the baseline (T = 0) data.
Sampling performed at day = 0, 1, 2, 4 and 7 for low/high conc.
Sampling performed at day = 0, 1, 2, 3 and 7 for common conc.
Sampling
number
Three independent batches Three independent batches, one batch at each concentration
Three replicates per batch Four independent replicate containers within each batch
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stored over a 7 day period in ready to use form at a range of
clinically relevant concentrations. Furthermore, the testing meth-
ods and techniques employed here are fully compliant with
guidance criteria set out by the NHS (UK) and, as such, constitute a
reliable study for the application of an extended shelf-life to the
clinical product when prepared under Section 10 exemption or a
Specials Licence. To the best of our knowledge, this report
represents the only published study currently compliant with
national guidelines in the UK to apply an extended shelf-life to this
class of product.
2. Study design
Guidance provided by the NHS (UK) was used as a template for
both the design of study methods, as well as the combination of
analytical techniques employed (Santillo, 2012). All guidance
requirements for the design of a robust stability study are detailed
in Table 1, along with the elements employed in this study.Table 2
NHS guidance requirements for a robust testing methodology and the methods emplo
Test methodology Guidance recommendation Methodology emp
Forced
degradation
A combination of some of: Impact of acid, ba
each technique(a) Change in pH
(b) Realistic elevated temperature
(c) Exposure to UV light
(d) Agitation
Visual
characteristics
Colour, clarity and particulates Visual inspection 
pH Changes to pH Evaluation of pH
Sub-visible
particulates
Evaluate particle levels over necessary range
(1–100 mm)
Quantiﬁcation of 
Physico-chemical
analysis
Should comprise a combination of: Techniques used i
(Tapestation) and(a) SEC
(b) DLS
(c) CEX
(d) Capillary or SDS electrophoresis
(e) Circular dichroism
(f) FT IR
Chemical Can comprise of:
(a) HPLC
HPLC-mass spectr
(b) UV
(c) Mass spectrometry
Biological activity Relevant to speciﬁc pharmaceutical action.
Can comprise any of:
Cell based assays 
(a) Biochemical (ELISA)
(b) Cell based
(c) Animal2.1. Study elements
Polyoleﬁn (Freeﬂex1) infusion bags were chosen as storage
containers and all drug samples were diluted using 0.9% sodium
chloride solution.
It is required by guidance that both clinically low and high
concentrations be studied, so that if the drug shows a consistent
stability proﬁle it should be possible to interpolate stability
between the concentrations studied. However, given the complex-
ity and inherent variability of this drug class, it was decided that
the study should exceed guidance requirements and three
concentrations of drug needed to be studied here. As such, this
study evaluated clinically low (0.60 mg/mL), clinically high
(1.88 mg/mL) and clinically common (0.84 mg/mL) concentrations
of drug.
It is recommended that two storage conditions are employed,
refrigerated (2–8 C) for the period of the study and room
temperature (25 C) for 24 h. This study evaluated all three
concentrations of drug under refrigerated storage (in the absence
of light) for the period of the study, as well as the clinically
common concentration (0.84 mg/mL) stored at 25 C for 24 h
(exposed to light) to represent in-use conditions.yed in this study.
loyed in this study
se, oxidation and exposure to light (natural and ﬂuorescent) were evaluated for
of colour, clarity and particulates
sub-visual particles (1–100 mm) using FlowCam
nclude SEC, DLS, variable temperature circular dichroism, SDS electrophoresis
 HPLC-mass spectrometry
oscopy performed on intact antibody and individual amino acid chains
measuring % viability of WEHI cells
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applicable to the data but as short as practicable. Sampling strategy
was designed to include the required number of sampling points
for a 7 day study, those being four sampling points in addition to
baseline (T = 0) data.
For adequate sampling numbers, three independent batches are
required,with each batchneedingto be evaluatedin triplicate. Again,
given the complexityand inherent variabilityof this drug class, it was
decided that the studyshould evaluate morereplicate devices within
each batch. As such, four independent replicate devices were
prepared for each of the three batches (one batch at each
concentration of drug), meaning that a total of 12 individual storage
containers were prepared. Additionally, to perform a truly represen-
tative evaluation of batch-to-batch variation during manufacturing,
the batch of drugs at clinically common concentration (0.84 mg/mL)
were prepared (and subsequently analysed) two weeks apart from
the batches of clinically low and high concentrations.
2.2. Test methodology
Biopharmaceuticals degrade through a wide variety of path-
ways and, as such, a range of analytical techniques are required to
adequately evaluate the physical, chemical and functional integrity
of these molecules when stored for extended periods of time. NHS
guidance provides a series of criteria that must be addressed for
the evaluation of stability to be considered robust (Table 2)
(Santillo, 2012).
Forced degradation studies need to be performed to demon-
strate the stability indicating nature of the analysis methods
employed. The stress conditions employed here to degrade
Remsima were chosen on the basis that they represent the most
likely forms of stress to be encountered during use. As such,
degradation resulting from changes to pH (high and low),
oxidation, or exposure to light were demonstrated at room
temperature for all appropriate analysis methods (online Supple-
mental data).
The visual characteristics of all test samples were evaluated to
detect gross physical changes to the drug by inspection of colour,
clarity and presence of visible particulates.
The stability of monoclonal antibodies is highly dependent on
the pH of the solution, which may change over time due to
interactions with excipients, infusion bag materials or as a result of
protein degradation. As such, the pH of drug solution was
evaluated in triplicate for all test samples.
The presence of sub-visible particles over the range 1–100 mm
was evaluated by particle imaging (FlowCam1, Fluid Imaging
Technologies) as this technique provides several advantages to
alternative methods, such as turbidity measurements. In particu-
lar, particle imaging provides a quantitative assessment of particle
numbers, as well as the ability to characterise the type of particle
detected (i.e. silicon oil droplet, micro-air bubble, protein) which
can provide a more detailed understanding of degradation.
Evaluation of physico-chemical stability needs to assess
multiple structural and chemical aspects of the protein, requiring
a combination of several analytical techniques to be performed.
Here, size exclusion chromatography (SEC) and gel electrophoresis
(Tapestation 2200, Agilent) were used to identify signiﬁcant
changes in protein molecular weight, such as reversible protein
aggregation (dimerisation and trimerisation) or hydrolysis. Dy-
namic light scattering (DLS) was used to evaluate levels of
aggregates and particles over the range 10 nm–6 mm (percentage
abundance) as well as gross changes to tertiary and quaternary
structure (hydrodynamic radius). Variable temperature circular
dichroism (VT-CD) evaluated changes to secondary and tertiary
structure of the protein by determining percentage composition of
a-helices and b-sheets, while melting temperature (Tm) providesan indication of changes to the chemical bonding (hydrogen
bonding, disulphide bridges) contributing to the stability of these
structures.
In-line HPLC-mass spectrometry was used to provide a
comprehensive evaluation of chemical changes to the antibody.
This technique was chosen as any observed mass differences can be
used to characterise speciﬁc chemical modiﬁcations occurring,
such as deamination, oxidation, deglycosylation and hydrolysis.
For the evaluation of changes to functional activity, a cell based
assay based on the procedure of Espevik and Nissen-Meyer was
chosen (Espevik and Nissen-Meyer, 1986). This method provides a
direct measure of the biological activity responsible for the
therapeutic effect of the drug, as required by NHS guidance
(Santillo, 2012).
3. Materials and methods
3.1. Reagents
Sodium phosphate monobasic, sodium phosphate dibasic
dihydrate and sodium chloride were obtained from Sigma–Aldrich
(Gillingham, Dorset, UK) and were of Analytical Reagent or HPLC
Grade. Water used for the preparation of buffers and other
analytical solutions was of HPLC Grade (Chromasolv1) and
obtained from Sigma–Aldrich. Water for injections was obtained
from Baxter Ltd.1 (Thetford, Cambridgeshire. UK). RPMI 1640, heat
inactivated foetal bovine serum (FBS), Penicillin/Streptomycin,
Phosphate Buffered Saline (PBS), HyQtase and MTT were all
purchased from Gibco. Tris(3-hydroxypropyl) phosphine (THPP)
was purchased from Sigma–Aldrich.
3.2. Materials
Remsima1 100 mg vials (BN: 14B1M016DC1, expiry 03/2019)
were obtained from NAPP Pharmaceuticals (Thetford, Cambridge-
shire, UK). Freeﬂex1 infusion bags of sodium chloride 0.9% sterile
solution for infusion were used for storage and sample dilution and
were obtained from Fresenius Kabi (Runcorn, Cheshire, UK).
Lubricant-free luer-lock Injekt1 syringes (BN: 4606728V) were
obtained from B. Braun (Melsungen, Germany). WEHI 164 cells
(ATCC; CRL-1751) were purchased from ATCC. Corning T75 tissue
culture treated ﬂasks and Nunc TC-treated Flat bottomed 96 well
plates were purchased from Fisher Scientiﬁc. TNF-a and Actino-
mycin D were purchased from RnD Systems.
3.3. Methods
Remsima1 products under study were prepared under aseptic
conditions in line with Good Manufacturing Practice, using
validated pharmacy procedures and in full accordance with
instructions outlined within the Summary of manufacturers
Product Characteristics for Remsima1 (Electronic Medicines
Compendium, 2015a). Products were prepared at three concen-
trations of 1.88 mg/mL, 0.84 mg/mL and 0.60 mg/mL by recon-
stituting the vials with water for injection to give a 10 mL
concentrated stock solution. The stock solution was added to a
Freeﬂex1 polyoleﬁn infusion bag of sodium chloride 0.9% and
stored at 2–8 C in light-protective bags. On the day of analysis,
samples were removed from each test product bag using aseptic
technique by withdrawing 4–5 mL into a lubricant-free syringe,
which was capped and stored at 2–8 C during the analysis period.
All test products were prepared in quadruplicate thus a total of
4 bags at 1.88 mg/mL, 4 bags at 0.84 mg/mL and 4 bags at 0.60 mg/
mL were compounded and used for analysis.
Samples were analysed on the day of test product preparation
(Day 0) and then at days 1, 2, 4 and 7 for batches at 1.88 mg/mL and
Fig. 1. Mean pH proﬁle of Remsima1 for 0.60 mg/mL, 0.84 mg/mL and 1.88 mg/mL solutions over the study period (n = 4). Error bars represent  1 SD.
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preparation (Day 0) and then at days 1, 2, 3 and 7 for the batch at
0.84 mg/mL. Test product samples were analysed using the listed
range of physico-chemical and biological techniques to assess the
physical, chemical and functional stability proﬁles of Remsima1 at
each time point.
3.4. Forced degradation
The stability indicating nature of each method was demon-
strated through forced degradation studies (Supplemental online
data). A range of degradation pathways were assessed by
subjecting freshly prepared samples of diluted Remsima1Fig. 2. Mean particle number results from FlowCam imaging of Remsima1 at (A) 0.60 
>10 mm are shown in blue and particles > 25 mm are shown in orange. Error bars repr(1.5 mg/mL in 0.9% NaCl solution) to several stress conditions
which included low pH (10 mM HCl), high pH (10 mM NaOH),
oxidation (2% hydrogen peroxide) and exposure to ﬂuorescent light
(Manning et al., 2010). All samples were analysed immediately
following stress.
3.5. Visual characteristics
Prior to any analytical methods being performed, samples were
checked by the unaided eye under normal laboratory ﬂuorescent
light for evidence of particulates, precipitation, colour change and/
or turbidity.mg/mL, (B) 0.84 mg/mL and (C) 1.88 mg/mL, over the period of the study. Particles
esent  1 SD.
Fig. 3. Representative overlay of SE-HPLC chromatograms of Remsima (1.88 mg/mL) at Days 0, 1, 2, 4, and 7. Samples at each time point were run in triplicate and an average
peak-signal calculated.
Table 3
SE-HPLC analysis of Remsima monomer concentration given as mean AUC
(mAU min) over the period of the study for clinically high (1.88 mg/mL), clinically
common (0.84 mg/mL) and clinically low (0.60 mg/mL) batches. Each batch
contains 4 replicate devices, with each device tested in triplicate.
Day
0 1 2 4 7
1.88 mg/mL 103.41 103.27 102.57 103.26 103.28
100.16 99.92 99.68 100.01 99.67
103.47 102.91 102.44 102.13 102.88
105.76 105.72 105.05 104.98 105.18
Mean AUC 103.20 102.95 102.43 102.59 102.75
S.D. 2.30 2.38 2.19 2.08 2.29
Day
0 1 2 3 7
0.84 mg/mL 46.41 46.48 46.36 46.37 46.41
45.3 45.26 45.09 45.40 45.19
45.99 45.74 45.79 45.83 45.70
45.73 45.42 45.58 45.69 45.29
Mean AUC 45.86 45.72 45.71 45.85 45.65
S.D. 0.47 0.54 0.53 0.41 0.56
Day
0 1 2 4 7
0.60 mg/mL 33.03 32.74 32.48 32.64 32.81
34.79 34.46 34.67 34.38 34.48
32.66 32.78 32.52 32.34 32.65
34.67 34.50 34.46 34.32 34.45
Mean AUC 33.79 33.62 33.53 33.42 33.60
S.D. 1.10 0.99 1.20 1.08 1.00
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Samples were tested using a Jenway 3510 pH Meter and
924007 electrode (Bibby Scientiﬁc, Staffordshire, UK) which was
calibrated prior to use at pH 4.00, 7.00 and 14.00. Triplicate pH
measurements were taken for each sample tested and results are
presented as the mean average of the triplicate measurements.
3.7. Sub-visible particle counting
Particle counting was performed using a FlowCAM VS instru-
ment (Fluid Imaging Technologies Inc., MA, USA) ﬁtted with an
FC100FV ﬂow cell and able to detect and quantify particles of 1–
100 mm in size. Flow rate was set to run at 0.15 mL/min, with an
imaging rate of 20 frames per second and an efﬁciency of 30.2%.
System calibration was performed using 10 mm polysorbate beads
(Sigma–Aldrich). Data was analysed using Visual Spreadsheet
software (v. 3.0.3). The stability indicating nature of this method
was conﬁrmed through forced degradation studies.
3.8. Physico-chemical analysis
3.8.1. SE-HPLC
Size exclusion HPLC as performed on an Ultimate 3000 system
(Dionex, Sunnyvale, CA, USA), consisting of an LPG-3400BM pump,
a WPS-3000TBFC analytical autosampler, a TCC-3000SD column
oven and a VWD-3100 detector. The samples were eluted on a
TSKGel1 G4000SWXL column (TOSOH BioScience, Stuttgart,
Germany) with dimensions 7.8  300 mm and particle size 8 mm
450 Å. The mobile phase was 300 mM NaCl + 50 mM Na3PO4 buffer
at pH 6.8 in HPLC grade water. The injection volume was 20 mL,
with an isocratic ﬂow rate of 0.5 mL/min over 30 min and UV
absorbance measured at 280 nm. Data was acquired and analysed
using Dionex1 Chromeleon software (v 6.8). Drug concentrations
were obtained from peak signal area by the use of a linear
regression curve of Remsima1 concentration vs absorption. Full
validation of the HPLC method was performed. This included
demonstration of accuracy, precision and linearity over the range
of concentrations tested, as well as demonstrating that limits of
detection (LOD) and quantiﬁcation (LOQ) were sufﬁcient for robustevaluation of protein characteristics (online Supplemental data).
The stability indicating nature of this method was conﬁrmed
through forced degradation studies.
3.8.2. Dynamic light scattering
Samples were analysed undiluted on a Zetasizer Nano-S
instrument at 20 C (Malvern Instruments., Worcs., UK) using a
red laser at a wavelength of 633 nm and a Hellma Quartz-Suprasil
cuvette Type 105.251.005-QS. The light path and centre were set at
3  3 mm and 9.65 mm, respectively. All data was recorded based
on intensity and converted to relative percentage by volume using
4.0%
6.0%
8.0%
10.0%
25 30 35 40 45 50 55 60 65 70 75 80 85 90
D0 D1 D2 D4 D7
28.0%
30.0%
32.0%
34.0%
36.0%
38.0%
40.0%
42.0%
25 30 35 40 45 50 55 60 65 70 75 80 85 90
D0 D1 D2 D4 D7
Temperature  (°C)
Temperature  (°C)

-
ecn adnuba
xileh
-
ecnadnub ateehs
A
B
Fig. 4. Variable temperature circular dichroism data for Remsima1 samples at 1.88 mg/mL showing structural abundance of (A) a-helix, and (B) b-sheet as a percentage of
the total protein. Measured over a temperature range of 25 to 90 C.
Table 4
Deconvoluted CD data for Remsima1 samples at 0.60 mg/mL, 0.84 mg/mL and
1.88 mg/mL (acquired at 76 C) over the period of the study. All values stated are
given as the percentage of total structural abundance in a-helix or b-sheets.
Day 0 Day 1 Day 2 Day 3 Day 4 Day 7
mg/mL a b a b a b a b a b a b
0.6 8.3 33.2 8.6 32.7 9.7 30.7 9.3 31.7 9 31.7
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indicating nature of this method was conﬁrmed through forced
degradation studies.
3.8.3. Gel electrophoresis
Protein separation analysis was conducted using samples which
were diluted to a concentration of 0.5 mg/mL with HPLC grade
water. Samples were analysed with the Screen Tape P200 Protein
Standard Kit (Part number: 5067–5371, Agilent) under reducing
and non-reducing conditions using P200 Reagents (Part number:
5067–5372) on a 2200 Tape Station system (Agilent1 Technolo-
gies, Waldbronn, Germany) according to the manufacturer's
instructions. The “P200 Markers (pre-stained)” (Agilent) was used
as a molecular marker. The stability indicating nature of this
method was conﬁrmed through forced degradation studies.
3.8.4. Variable temperature circular dichroism
Variable temperature Circular Dichroism was performed using
a Chirascan spectrophotometer (Applied Photophysics Ltd., Surrey,
UK). Samples from each test product bag were pooled and diluted
to a concentration of 0.25–0.3 mg/mL with sodium chloride 0.9%
and tested using a Quartz Suprasil Cuvette (Hellma Analytics,
Essex, UK) of pathlength 0.1 cm. CD spectra were collected in the
far-UV region (205–260 nm) over a temperature range of 25–90 C
in steps of +1 C/min. Final CD spectra were adjusted against the
blank (NaCl 0.9%) and analysed using CDNN deconvolution
software (v2.1) to yield composition percentages of secondary
structures identiﬁed as of alpha-helices, parallel, anti-parallel,
beta-turn and random coil structure. The stability indicatingnature of this method was conﬁrmed through forced degradation
studies.
3.8.5. LC mass spectroscopy
Mass spectroscopy was conducted using a 6520 Accurate-Mass
Q-TOF mass analyser instrument (Agilent1, Germany). Samples
were desalted by centrifugation at 4000 rpm for 30 min and rinsing
with HPLC Grade Water. This process being repeated 4 times to
ensure complete salt removal and therefore avoiding interference
of ionisation by the presence of sodium chloride. Samples of 0.5 mL
were then reduced by adding 5 molar equivalents of THPP. This also
allows for the generation of separate spectra proﬁling ions which
are derived from both the heavy and light chain. The stability
indicating nature of this method was conﬁrmed through forced
degradation studies.
3.9. Biological activity
The biological activity of Remsima1 samples was assessed by
their ability to inhibit TNF-a induced cell death in the WEHI cell0.84 8.2 33.1 8.4 32.9 7.9 33.6 7.9 33.7 8 33.8
1.88 8.2 33.6 10 29.9 7.7 34.3 7.2 35.1 9.1 31.9
Fig. 5. Averaged particle radius of 1.88 mg/mL, 0.84 mg/mL and 0.60 mg/mL Remsima1 samples over the course of 7 days as determined by Dynamic Light Scattering. Each
time point consisted of 4 different samples at each concentration, which in turn were run in triplicate to provide an average measurement for each bag (n = 12).
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and Nissen-Meyer, 1986). Cells were harvested from culture and
added to a 96 well plate at 1.5 104 cells/well and incubated for 2
at 37 C for the cells to adhere. Remsima samples were diluted to
1 mg/mL in saline and incubated with 10 pg/mL TNF-a for 30 min.
The TNF-a antibody mixture was then added to the cells and 2 mg/
mL Actinomycin D added to the wells. Assay plates were incubated
for a further 18 h at 37 C. Cell viability was then assessed using an
MTT assay. To analyse the results, the absorbance at 540 nm (A540)
of cells exposed to TNF-a was set as background and subtracted
from all values. A540 of cells not exposed to TNF-a (negative
control) was set to 100%. Percent cell viability was then calculated
as (A540 sample/A540 negative control)  100. Values were then
indexed against values obtained for day 0 vial samples of
inﬂiximab to control for inter-assay variability. Each sample was
tested in quintuplicate and the mean and standard deviation
calculated. The stability indicating nature of this assay method was
conﬁrmed through forced degradation studies.
4. Results
4.1. Visual inspection
All samples remained clear for the duration of the study with no
precipitates or particulate matter detected with the naked eye. No
change in colour or turbidity was observed over the study period.
Photographs of all storage devices tested at each time point are
provided in the online Supplemental data.Table 5
Averaged drug abundance (percentage) of 1.88 mg/mL, 0.84 mg/mL and 0.60 mg/mL Re
Day 0
(SEM)
Day 1
(SEM)
Day
(SEM
1.88 mg/mL 99.82
(0.12)
99.85
(0.03)
99.9
(0.
0.84 mg/mL 99.52
(0.24)
99.28
(0.12)
99.5
(0.
0.60 mg/mL 99.83
(0.10)
99.93
(0.06)
99.9
(0.4.2. pH
No signiﬁcant change was observed for the pH of samples at any
of the concentrations tested throughout the study period (Fig. 1).
The pH of samples at 1.88 mg/mL and 0.84 mg/mL were very
similar at around pH 6.9, while the pH of the most dilute samples at
0.60 mg/mL was noticeably lower at pH 6.6, possibly reﬂecting the
buffering capacity of excipients. Slight variability in pH readings
(0.1 pH units) was observed for all concentrations, however this
variability was not signiﬁcant as the observed pH’s at day 7 showed
almost no change from their respective pH’s at day 0, for all
concentrations.
4.3. Sub-visible particle counting
Quantiﬁcation of particle numbers was carried for particles
>10 mm and >25 mm in size. At all concentrations tested, the
number of particles >10 mm was signiﬁcantly higher than the
number of particles >25 mm for all time points. Also, as is common
with ﬂow imaging techniques, the standard deviations for replicate
samples was found to be quite large, making a detailed statistical
analysis of results difﬁcult. However, for all concentrations tested
the largest variations in particle numbers appeared to be between
the early time points (day 0, 1 and 2), with particle numbers
appearing to remain relatively constant past day 2. Importantly,
there appeared to be no appreciable change in average particle
numbers between samples at day 0 and day 7, for any of the
concentrations tested Fig. 2.msima1 samples over the course of 7 days as determined by DLS.
 2
)
Day 3
(SEM)
Day 4
(SEM)
Day 7
(SEM)
8
02)
99.92
(0.04)
99.92
(0.02)
9
05)
99.65
(0.29)
99.77
(0.05)
06)
99.79
(0.09)
99.84
(0.05)
Fig. 6. Protein separation analysis of and Remsima1 samples (5 mg per well) showing (A) Day 0 for 1.88 mg/mL and 0.60 mg/mL, (B) Day 7 for 1.88 mg/mL and 0.60 mg/mL, (C)
Day 0 for 0.84 mg/mL and (D) Day 7 for 0.84 mg/mL. Lane 1 in all gels is a protein ladder standard.
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All HPLC chromatograms of Remsima1were characterised by a
single major peak with an elution time of 21.6 min (Fig. 3). For the
clinically high concentration batch (1.88 mg/mL) this comprised,
on average, 99.28% (0.15%) of all detected signals over the course
of the study. A minor signal with a retention time around 20.0 min
was also observed at this concentration, which comprised the
remaining 0.73% of observed signals. This minor peak was assigned
as Remsima dimer on the basis of the retention time equating to a
molecular weight of 300 kDa, according to a standard protein curve
(online Supplemental data). Chromatograms obtained from
samples at 0.84 mg/mL and 0.60 mg/mL comprised of only a single
peak corresponding to the Remsima monomer.
Importantly, no change in the intensity of signals was observed
for any of the batches over the period of the study, indicating that the
concentration of Remsima remained constant throughout (Table 3).
4.5. Variable temperature CD
Analysis of variable temperature circular dichroism spectra
indicates the protein undergoes its most signiﬁcant changes to
secondary structure induced by thermal degradation over the
temperature range 74–78 C (Fig. 4). This temperature range
remained largely constant throughout the study period for all
concentrations tested.
The percentage composition of secondary structures (a-helix
and b-sheet) measured at 76 C was found to vary slightly over the
course of the study, though no appreciable changes were observed.For the more concentrated samples (1.88 mg/mL), a-helix content
varied between 7.2% and 10% during the study, while b-sheet
varied between 29.9% and 35.1%. At this concentration, the samples
at day 1 showed the greatest deviation from results at other time
points whilst, importantly, day 7 data fell between the range of the
early time points (day 0 and day 1) Table 4.
For the more diluted samples (0.60 mg/mL), slightly less
variation in secondary structure was observed, with a-helix
content varying between 8.3% and 9.7% during the study, while
b-sheet varied between 30.7% and 33.2%. At this concentration
it was the day 2 samples that showed the greatest deviation
from results at other time points, indicating that changes to
secondary structure may be occurring slower than for the
higher concentration samples. Additionally, for both the high
and low concentrations, it is the early time points in the study
that exhibit the greatest degree of variations in secondary
structure.
4.6. Dynamic light scattering
Dynamic light scattering results are expressed as the mean
radius and percentage abundance of detected drug particles within
the test solution (Fig. 5). A signiﬁcantly larger mean radius could
suggest the formation of aggregates which have a greater spherical
volume, while a decrease in percentage abundance of drug could
be attributed to larger aggregate formation. The measured drug
radii were found to be similar for all concentrations throughout the
study, ranging from 14.3 to 15.1 nm immediately after preparation
on day 0, to 12.9–15.2 nm on day 7.
Fig. 7. Comparison of LC–MS spectra for samples of Remsima stored at 0.60 mg/mL. Day 0 (top) vs Day 7 (bottom) spectra are compared for (A) light chain and (B) heavy chain.
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remained constant over the study period, demonstrating that
there was no signiﬁcant increase in the number of larger particles
(<6 mm) at any of the concentrations (Table 5).
4.7. SDS gel electrophoresis
Protein separation of day 0 samples for all concentrations was
characterised by a single band of approximately 150 kDa for the
native (non-reduced) samples and two bands of approximately
50 kDa and 25 kDa for the reduced samples (Fig. 6A and C). Nochange to either the molecular weight or intensity of the bands was
observed for any samples throughout the study period for all
concentrations, as is demonstrated by the day 7 samples shown
(Fig. 6B and D).
4.8. LC mass spectroscopy
Mass spectral analysis of the light chain of Remsima on day
0 across all concentrations is characterised by a single major
species of mass 23.4 kDa (Fig. 7A). The mass of this species
remained constant over the study period, with no additional peaks
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Fig. 8. Functional activity of Remsima was tested by its ability to neutralise TNF-a
in a WEHI cell death assay. Remsima was tested at 1 mg/mL and results indexed
against results for Remicade to control for inter assay variation. Data shown are
mean with SD of pooled results for each concentration.
Table 6
Statistical analysis of functional activity. Data shown in Fig. 8 were subjected to an
unpaired t-test using GraphPad Prism version 5.04 for Windows (GraphPad
Software, La Jolla California USA, www.graphpad.com). Day 0 was compared with
Day 1 (the SPC limit) and subsequently, Day 7 with Day 1.
Data tested D1 vs D0 D1 vs D7
1.88 mg/mL p-value 0.011 0.2877
Are means sig diff? Yes No
Summary * ns
Data tested D1 vs D0 D1 vs D7
0.6 mg/mL p-value 0.0016 0.2777
Are means sig diff? Yes No
Summary ** ns
Data tested D1 vs D0 D1 vs D7
0.84 mg/mL p-value <0.0001 0.3053
Are means sig diff? Yes No
Summary **** ns
ns denotes not signiﬁcant (P > 0.05).
* Signiﬁcant (P  0.05).
** Very signiﬁcant (P  0.01).
**** Extremely signiﬁcant (P  0.0001).
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did not change (online Supplemental data).
The mass spectrum of the heavy chain of Remsima is
characterised by a series of molecular ion peaks of around
51 kDa in mass (Fig. 7B). The complexity of this spectra is
characteristic of antibody heavy chains owing to the heterogeneity
of N-linked glycan proﬁles. Comparison of the heavy chain mass
spectra at day 0 and day 7 (for all concentrations) revealed no
obvious change in chemical composition at any point during the
study period. Importantly, this technique demonstrates the
stability of the primary peptide chain, as well as the glycan proﬁle
of the antibody which can inﬂuence functional activity and
pharmacokinetics of the protein.
4.9. Biological activity
Samples of diluted Remsima typically prevented around 80% of
the TNF-a induced death of WEHI cells when tested at 1 mg/mL in
this assay. This level of biological activity was equivalent to that
observed for freshly prepared samples of Remicade (1 mg/mL).
Samples of Remsima tested at Day 0 showed the most dramatic
variability in biological activity, both across the three concen-
trations (batches) and within each batch (Fig. 8). This variability in
activity appeared to diminish over the period of the study, suchthat Day 7 data demonstrated the least amount of inter- and intra-
batch variability. Owing to the variability in the data, statistical
analysis (t-test) was performed to identify changes of signiﬁcance
in the biological activity of the drug. Day 1 (SmPC limit) data was
compared to both Day 0 and Day 7 data, with results presented in
Table 6. Interestingly, analysis demonstrated a statistically
signiﬁcance in biological activity between Day 0 and Day 1 samples
(within the SmPC assigned shelf-life) at all concentrations tested.
However, no signiﬁcance was observed to differences between
activities at Day 1 and Day 7, across all concentrations.
5. Discussion
This study has employed study design and testing methodology
which are compliant with NHS guidance requirements for
performing a robust evaluation of antibody stability over a period
of extended storage. We have used a number of analytical and
biological techniques to evaluate the stability of diluted solutions
of Remsima for a period of 7 days. Overall, no chemical or physical
instability was observed, while the drug was also found to retain
full biological activity.
The techniques of LC–MS, SE-HPLC and gel electrophoresis
showed no change for any sample examined throughout the study,
indicating that full integrity of the chemical structure (protein and
carbohydrate) of the drug is retained.
However, variable temperature circular dichroism does indicate
minor changes in the secondary structure of the drug immediately
following dilution, which appears to be accompanied by variability
in numbers of particles >10 mm in size. These observations are not
surprising, as dilution of the excipients results in a dramatic
reorganisation of protein surface interactions. In all cases however,
the observed variability is reduced over time as the drug gradually
reaches equilibrium under new conditions.
It is also of interest to note that, although minor, the initial
changes to secondary structure and variability in particle number
do appear to show a measurable impact upon the biological
activity of the drug. A statistically signiﬁcant difference can be
attributed to the mean activities of day 0 and day 1 samples, whilst
no such difference is present between day 1 and day 7 samples. In
totality, these results suggest that the process of drug dilution
contributes a more dramatic impact on drug quality than does
extended storage, at least over the storage period studied here.
6. Conclusions
Here we have demonstrated the stability of Remsima1 over a
7 day period when diluted in sodium chloride solution and stored
in polyoleﬁn bags at 2–8 C. A range of analytical techniques were
used to assess the physico-chemical and functional integrity of the
drug over time. Furthermore, the methods and techniques used
here are fully compliant with NHS (UK) guidance for evaluating the
stability of biologicals, enabling this data to be used for the
application of 7 day shelf-life to Remsima products, when prepared
under a Section 10 exemption or a Specials License and according
to the methods presented here.
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